Table 4 Treatment modalities combined with targeting m7G for cancer treatment in preclinical and clinical settings
From: N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential
Type of cancer | Treatment modalities | Target | Effect | References |
|---|---|---|---|---|
Intrahepatic cholangiocarcinoma | SB225002 and anti-PD-1 therapy | METTL1-mediated m7G tRNA modification | Inhibits MDSC recruitment and improves anti-PD-1 efficacy | [50] |
Prostate cancer | Anti-PD1 and anti-CTLA4 therapy | METTL1 | Enhances the response to immunotherapy | [82] |
Head and neck squamous cell carcinoma | BKM120 | METTL1 | Prevents HNSCC progression | [123] |
Hepatocellular Carcinoma | Radiofrequency ablation | METTL1 | Prevents HCC recurrence after RFA | [170] |